AB-206に関する基礎的ならびに臨床的研究

DOI Web Site

書誌事項

タイトル別名
  • FUNDAMENTAL AND CLINICAL STUDIES ON AB-206
  • AB 206 ニ カンスル キソテキ ナラビニ リンショウテキ ケンキュウ

この論文をさがす

抄録

Antibacterial activities and clinical effects of AB-206, a new chemotherapeutic agent, were investigated and the results were as follows:<BR>1. Antibacterial activity of AB-206 against clinically isolated bacteria and the distribution of susceptibility to their strains were studied. The peaks of distribution of susceptibility were 6.25μg/ml in Staphylococcus aureus, 0.39μg/ml in E. coli, 0.78μg/ml in Klebsiella, 0.39μg/ml in Proteus sp., and 25μg/ml in Pseudomonas aeruginosa, tested by small inoculum size.<BR>Compared with the antibacterial activity of pipemidic acid, that of AB-206 was more potent on gram-negative bacteria except for P. aeruginosa.<BR>2. A total of 8 patients with bacterial infections, including 1 case of acute cystitis, 4 cases of chronic cystitis, 2 cases of chronic pyelonephritis and 1 case of bronchiectasis with infection, underwent treatment with AB-206. The drug was administered orally for 2-27 days at doses of 1-2g/ day. The clinical effects were excellent in 2 cases, good in 3 cases, fair in 1 case and poor in 2 cases. As side effect, temporary elevation of GOT and GPT was observed in 1 case.

収録刊行物

詳細情報 詳細情報について

問題の指摘

ページトップへ